Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 1

Interventions

pembrolizumab 95Specimen Handling 79Magnetic Resonance Spectroscopy 70Carboplatin 59Cisplatin 56Biopsy 56Nivolumab 51Radiotherapy 47Cyclophosphamide 44Paclitaxel 43Radiation 36durvalumab 33Gemcitabine 31olaparib 30Dexamethasone 30Etoposide 29Doxorubicin 28atezolizumab 26Taxes 25Rituximab 25Docetaxel 25Ipilimumab 24Bevacizumab 24Vincristine 23Lenalidomide 23Pemetrexed 22Cytarabine 22X-Rays 21Radiotherapy, Intensity-Modulated 21Prednisone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Clofarabine × 90 days × Clear all
NCT02883049 2026-06-02

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

National Cancer Institute (NCI)

Phase 3 Completed
5,949 enrolled 28 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡